D82.3 Immunodeficiency following hereditary defective response to Epstein-Barr virus

Name of the Condition

• Immunodeficiency following hereditary defective response to Epstein-Barr virus

Summary

Immunodeficiency following hereditary defective response to Epstein-Barr virus is a primary immunodeficiency disorder characterized by an impaired immune response to Epstein-Barr virus (EBV) due to genetic defects. This condition increases susceptibility to severe or persistent EBV infections, which can lead to complications such as lymphoproliferative disorders or organ damage. The immune dysfunction is specific to EBV, though other infections may also occur depending on the extent of broader immune impairment.

Causes

The condition is caused by genetic mutations that disrupt the normal immune response to Epstein-Barr virus. These mutations typically affect genes involved in T-cell or natural killer (NK) cell function, which are critical for controlling EBV infection. The defects are hereditary and may be inherited in an autosomal recessive or X-linked pattern, depending on the specific genetic abnormality.

Risk Factors

• Genetic mutations affecting EBV-specific immune responses
• Family history of primary immunodeficiencies
• Inherited disorders of T-cell or NK-cell function

Symptoms

• Severe or prolonged Epstein-Barr virus infection (e.g., infectious mononucleosis)
• Lymphoproliferative disorders (e.g., lymphoma)
• Organ damage from uncontrolled viral replication
• Recurrent or opportunistic infections (if broader immune dysfunction is present)

Diagnosis

Diagnosis involves clinical evaluation of EBV infection severity, genetic testing to identify mutations in immune-related genes, and laboratory assessments of immune function (e.g., T-cell or NK-cell activity). Imaging or biopsy may be used to evaluate organ involvement from EBV-related complications. A confirmed genetic defect and abnormal immune response to EBV are key diagnostic criteria.

Treatment Options

Treatment focuses on managing EBV infections and preventing complications. Antiviral therapies (e.g., ganciclovir) may be used for active infections, while immunoglobulin replacement or hematopoietic stem cell transplantation can address underlying immune deficiencies. Supportive care, such as monitoring for organ damage, is also critical.

Prognosis and Follow-Up

Prognosis varies based on the severity of immune dysfunction and organ involvement. Early diagnosis and treatment improve outcomes, but severe cases may have higher risks of lymphoproliferative disease or organ failure. Regular follow-up with immunology specialists is recommended to monitor immune function and manage complications.

Complications

• Lymphoproliferative disorders (e.g., lymphoma)
• Organ damage from uncontrolled EBV replication
• Increased susceptibility to other infections (if broader immune impairment exists)

Lifestyle & Prevention

• Avoid exposure to EBV (e.g., through close contact with infected individuals)
• Practice good hygiene to reduce infection risk
• Follow vaccination schedules (where appropriate) to prevent other infections
• Maintain regular medical monitoring to detect complications early

When to Seek Professional Help

Seek medical attention if experiencing severe or prolonged symptoms of EBV infection, such as high fever, persistent fatigue, or swollen lymph nodes. Immediate care is needed for signs of organ involvement (e.g., jaundice, difficulty breathing) or uncontrolled infection.

Tips for Medical Coders

Document the hereditary nature of the immune defect and the specific response to Epstein-Barr virus. Include details of genetic testing results, immune function assessments, and any EBV-related complications to support code assignment. Ensure documentation aligns with the clinical criteria for immunodeficiency due to defective EBV response.